Insmed To Present at September Investor Conferences

Rhea-AI Summary

Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5 at 8:00 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9 at 4:50 p.m. ET.

Both presentations will be available via webcast through Insmed's investor relations website and will remain accessible for 30 days after the events.

News Market Reaction

+2.43%

1 alert

+2.43% News Effect

On the day this news was published, INSM gained 2.43%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRIDGEWATER, N.J., Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences:

• Wells Fargo 2025 Healthcare Conference in Boston, on Friday, September 5, 2025, at 8:00 a.m. ET.
• Morgan Stanely 23^rd Annual Global Healthcare Conference in New York, on Tuesday, September 9, 2025, at 4:50 p.m. ET.

These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html

SOURCE Insmed Incorporated

FAQ

When is Insmed presenting at the Wells Fargo Healthcare Conference 2025?

Insmed will present at the Wells Fargo Healthcare Conference in Boston on Friday, September 5, 2025, at 8:00 a.m. ET.

What time is Insmed's presentation at the Morgan Stanley Healthcare Conference 2025?

Insmed will present at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 9, 2025, at 4:50 p.m. ET.

How can investors access Insmed's September 2025 conference presentations?

Investors can access the live webcasts through the investor relations section of Insmed's website at www.insmed.com.

How long will Insmed's September 2025 conference webcasts be available?

The webcasts will be archived for 30 days following the conclusion of each live event.